ArticleScientific reports2020
Identification of putative biomarkers for Infantile Hemangiomas and Propranolol treatment via data integration.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- Research Progress on Angiogenesis and Involution Mechanisms of Infantile Hemangioma and Its Regulation by Active Components ofInternational journal of molecular sciences · 2026Review
- Review
- Integrative Bioinformatics Analysis and Machine Learning Reveal TSPAN7 Regulates the Involution of Infantile Hemangioma via NK Cells.Clinical, cosmetic and investigational dermatology · 2026Article
- Article
- Analysis of Necroptosis-Related Genes and Immune Cell Infiltration in Infantile Hemangioma.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Early plasma changes of HIF-1 alpha, matrix metalloproteinases-2 and - 9, and tissue inhibitor of matrix metalloproteinase-1 in patients with infantile hemangiomas treated with propranolol.Pharmacological reports : PR · 2025Article
- Identifying Potential Diagnostic and Therapeutic Targets for Infantile Hemangioma Using WGCNA and Machine Learning Algorithms.Biochemical genetics · 2025Article
- Dynamic serum biomarkers in infantile hemangioma: the role of VEGF-B, AKT, and eNOS in lesion regression.European journal of pediatrics · 2025Article
- MiR-27b-3p Reduces the Efficacy of Propranolol in the Treatment of Infantile Hemangioma by Inhibiting the Expression of Apaf-1.Biomedicines · 2025Article
- Decoding infantile hemangioma: cellular dynamics, molecular signals, and microenvironmental influences.Frontiers in oncology · 2025Review
- Hypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors.Frontiers in cell and developmental biology · 2025Review
- Integrative Bioinformatics Analysis of Pyroptosis-Related Genes and Analysis of Immune Cell Infiltration in Infantile Hemangioma Regression.Clinical, cosmetic and investigational dermatology · 2025Article
- Article
- Infantile hemangioma: the common and enigmatic vascular tumor.The Journal of clinical investigation · 2024Review
- Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation.Drug design, development and therapy · 2024Article
- Shikonin reverses pyruvate kinase isoform M2-mediated propranolol resistance in infantile hemangioma through reactive oxygen species-induced autophagic dysfunction.Cancer science · 2023Article
- Identification of novel potential biomarkers in infantile hemangioma via weighted gene co-expression network analysis.BMC pediatrics · 2022Article
- Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma.The Journal of clinical investigation · 2022Article
- Identification of Diagnostic Markers in Infantile Hemangiomas.Journal of oncology · 2022Article
- Transcriptional data analysis reveals the association between infantile hemangiomas and venous malformations.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Infantile hemangiomas (IHs) are the most common benign tumors in early childhood. They show a distinctive mechanism of tumor growth in which a rapid proliferative phase is followed by a regression phase (involution). Propranolol is an approved treatment for IHs, but its mechanism of action remains unclear. We integrated and harmonized microRNA and mRNA transcriptome data from newly generated microarray data on IHs with publicly available data on toxicological transcriptomics from propranolol exposure, and with microRNA data from IHs and propranolol exposure. We identified subsets of putative biomarkers for proliferation and involution as well as a small set of putative biomarkers for propranolol's mechanism of action for IHs, namely EPAS1, LASP1, SLC25A23, MYO1B, and ALDH1A1. Based on our integrative data approach and confirmatory experiments, we concluded that hypoxia in IHs is regulated by EPAS1 (HIF-2α) instead of HIF-1α, and also that propranolol-induced apoptosis in endothelial cells may occur via mitochondrial stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.